Daniel Moore Palhares, Hany, arjun sahgal, Sunnybrook Health Sciences Centre et al discuss temporal ADC changes during chemoradiation: An imaging biomarker for tumor response monitoring and spatial recurrence prediction in glioblastoma. Read about it in the #RedJournal: tinyurl.com/redsnbrk

📢data from SHERBET metà analysis: SBRT has excellent long-term efficacy with significantly decreased BCF compared to HDR-BT. #ESTRO25 ,ESTRO ,Dr. Andrew Loblaw

Surprising data from Sunnybrook Dr. Andrew Loblaw for higher BCR with HDR mono vs sbrt - controversy enough to crash the slides.

🔥⚡️🚀 First prospective comparison of SBRT vs HDR-BT in prostate cancer (SHERBET study): SBRT shows superior long-term efficacy & lower BCF. Two-fraction HDR-BT w/o ADT? Only in trials for intermediate-risk pts. Great work from Sunnybrook team! #RadOnc #GU25 Dr. Andrew Loblaw

Active Surveillance for Favorable intermediate risk prostate cancer. Safe option for select patients. Data presented on #ESTRO25 Dr. Andrew Loblaw Danny Vesprini

🚀 New in Journal of Clinical Oncology - ROBOMET shorturl.at/NawNo! SABR vs standard #radiotherapy for painful bone mets. ✅ Pain relief at 1 month: 🔹 SABR (20 Gy single dose): 37% complete response 🔸 versus (8 Gy): 25% complete response ⚡ at 3-months ⬆️ withSABR: 54% vs 31%, p= .048

1/3 Was lucky to present our ASTuTE trial interim results #ESTRO25 in Vienna Q: How does the @ArteraAI prostate test influence shared ST-ADT decision making - 200 patients, across 28 Australian centers (GenesisCare) - 150 UIR and 50 FIR prostate cancer - Only 15% biomarker +ve

Fantastic Grey Zone topic for June of 2025 Which Way to (INDI)GO? Case: 42 yo male with STR of a WHO grade 2 IDH mutant (IDH1 R132H) astrocytoma with loss of ATRX, no 1p/19q codeletion, and no homozygous deletion of CDKN2A/B. redjournal.org/article/S0360-… IJROBP - The Red Journal

Thank you to IJROBP - The Red Journal for giving Stanislav (Stas) Lazarev, MD and I the opportunity to contribute to the most recent Gray Zone case “The INDIGO Illusion: The Evidence Still Supports Chemoradiation Therapy in Patients with Low-Grade Glioma” redjournal.org/article/S0360-…

Our work on AI prediction of Radiation induced toxicity in lung cancers is out! Available via open access

Happy to co author this work which looks at patient selection and outcomes following local treatments for lung mets. Check it out! Open access

🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

🧠💥 Pre-op SRS for brain mets is gaining traction. But must we resect 1–3 days after? 🤔 We ran a small feasibility trial. Biological rationale: keeping the irradiated tumor in situ longer may allow immune responses within the tumor to develop🕒 link.springer.com/article/10.100…

- 15 pts - Median SRS-to-surgery: 8 days - No earlier surgery for growth / oedema - No Grade >2 AEs - No issues with histopath diagnosis - Interestingly, the only BrM failure at 13.8m f/u had a 0-day SRS-to-surgery interval - Lab analyses to follow! Peter Mac Radiation Oncology

Rubén Del Castillo does it again! RSNA Resident and Fellow Roentgen Research Award for his work identifying favourable intermediate patients where #ActiveSurveillance is safe. N=1699, mFU 10.3y 🟰 freedom from Mets for men with GG1 or GG2 with APP4 <5% Radiation Oncology arjun sahgal Laura Dawson

C. Jillian Tsai, MD, PhD Sushil Shankar Siva Also take note of the new phase 3 pharma destiny trial - primary endpoint is TNTT…clinicaltrials.gov/study/NCT05950… so pharma are interested in measures like this

First study I’m aware of that integrates PSMA & MRI to define DIL and then treats DIL, prostate and pelvis all in 5 SBRT treatments. Should we have called it Super-FLAME?

Also brachy vs EBRT, n=710, phase 3 international RCT CCTG PR24

👏🏽👏🏽👏🏽 agree! it’s time to retire the “toxicity” moniker #radonc. We are stuck in the past!!!! Sue Yom Neha Vapiwala

Thrilled to complete my first year of fellowship! 🙌 Immense gratitude to all my mentors, especially Dr. Andrew Loblaw for shaping me into a better RadOnc. Honored to meet future RadOnc stars! 🌟